Selective H-PGDS Inhibitors for Allergy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-steroidal anti-inflammatory drugs that inhibit cyclooxygenase have adverse effects such as gastric toxicity and cardiovascular complications due to their broad impact on prostaglandin production, highlighting the need for more specific targeting of prostaglandin D2 synthesis, particularly through inhibition of haematopoietic-prostaglandin D2 synthase (H-PGDS) to address inflammatory and allergic responses.
Innovation Solution
Development of novel compounds that selectively inhibit H-PGDS, as described by specific chemical formulas, which are administered to treat or prevent conditions associated with H-PGDS, such as allergies and inflammation, with a focus on compounds of formula (I), (II), and (III), and their use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclooxygenase is inhibited to reduce prostaglandin production, then inflammatory responses are suppressed, but gastric toxicity and cardiovascular complications occur due to broad impact on multiple prostaglandins
Solution Approach 1:
The patent segments the prostaglandin synthesis pathway by targeting a specific downstream enzyme (H-PGDS) rather than the upstream cyclooxygenase. This segmentation allows selective inhibition of PGD2 production while preserving other prostaglandins, thereby maintaining therapeutic effectiveness against inflammation and allergy while avoiding the harmful effects of broad cyclooxygenase inhibition.
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures (formula I, II, III) that selectively bind to H-PGDS enzyme active sites. This localized specificity ensures that only PGD2 synthesis is inhibited in affected tissues, preserving the functions of other prostaglandins in the stomach and cardiovascular system, thus eliminating gastric toxicity and cardiovascular complications.
2Adaptability or versatility
If H-PGDS is selectively inhibited to target PGD2 production, then specific biological effects are achieved without cyclooxygenase side effects, but compound selectivity and specificity must be precisely optimized
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular structure parameters (substituents R1-R6, ring structures, stereochemistry) in compounds of formula I, II, and III to optimize H-PGDS selectivity. Through structure-activity relationship studies, specific parameter ranges were identified that maximize enzymatic selectivity while minimizing off-target effects, achieving high adaptability without excessive complexity.
3Reliability
If broad cyclooxygenase inhibition is used to treat inflammation, then multiple prostaglandin pathways are affected, but this leads to loss of prostacyclin and adverse cardiovascular effects
Solution Approach 1:
The invention extracts the harmful effect by removing the inhibition of prostacyclin synthesis from the therapeutic mechanism. By taking out the cyclooxygenase inhibition step and directly targeting H-PGDS downstream, the patent selectively reduces PGD2 (the harmful mediator in allergy and inflammation) while preserving prostacyclin production, thereby eliminating cardiovascular complications while maintaining anti-inflammatory reliability.
Data Source
AI summary
The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.